Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy With Pemetrexed in Combination With Platinum for Advanced Non-Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Cytologically and/or histologically confirmed NSCLC Stage IIIb or IV~* No previous systemic chemotherapy for this cancer~* At least one uni-dimensionally measurable lesion meeting Response Evaluation Criteria In Solid Tumors (RECIST) criteria~* Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1 and adequate organ function~* Prior radiation therapy allowed but limited to \<25% of the patient's bone marrow~Exclusion Criteria:~* Serious concomitant systemic disorder or active infection~* Mild to moderate renal insufficiency, but unable to interrupt salicylates or other nonsteroidal anti-inflammatory drugs~* Symptomatic central nervous system (CNS) metastases requiring concurrent corticosteroid therapy~* Presence of clinically significant third-space fluid collections

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemetrexed + Cisplatin (Type: EXPERIMENTAL): None
- Pemetrexed + Carboplatin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).